Oscillo Biosciences has been awarded a competitive Phase I SBIR grant from the National Science Foundation (NSF), through America's Seed Fund — the NSF's program supporting early-stage innovation with strong commercial and societal potential.
The $224,846 grant supports the initial development of SynchronyGamma, Oscillo's music-based intervention for Alzheimer's disease and mild cognitive impairment.
This NSF award was a pivotal early validation of Oscillo's scientific approach. The NSF SBIR program funds only the most promising small business innovations — those that demonstrate both deep technical merit and clear potential for broad impact.
Oscillo's approach is rooted in the pioneering research of co-founders Dr. Edward Large and Dr. Ji Chul Kim, who demonstrated that the brain's neural oscillations can synchronize with musical stimuli through a process known as neural entrainment. By combining this foundational neuroscience with precisely designed audio-visual stimulation, Oscillo is developing non-invasive interventions that could meaningfully improve outcomes for the millions of individuals living with neurodegenerative diseases.
The NSF grant provided critical seed funding that helped Oscillo advance its research from laboratory findings toward clinical application — laying the groundwork for the subsequent NIH-funded clinical trial that is now underway.
Source: Oscillo Biosciences — https://oscillobiosciences.com/oscillo-biosciences-awarded-competitive-grant-from-the-nationalscience-foundation/